CD8A and neoplasm: The TCRs expressed by CD8 killer cells recognize pHLA complexes on tumor cells and are necessary and sufficient to mediate durable remissions across various types of cancer immunotherapies, including checkpoint inhibitors (CPIs), adoptive cell therapies and cancer vaccines (10–12).